Harrow (HROW) closed at $26.89 on November 6, 2026, up 3.3% from the previous close, on volume of 617,938 shares (30-day average 576,655).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Call Spread | 17-Dec-2740 : 50 C | 1,960 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Mon, 2-Nov 9:00 AM ET)
Harrow Launches HarrowRx Platform
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Harrow Closes Acquisition of TYRVAYA
Globe Newswire (Mon, 5-Oct 7:00 AM ET)
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
Globe Newswire (Wed, 30-Sep 7:00 AM ET)
Harrow to Participate in Three Investor Conferences in September
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Harrow Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections
Globe Newswire (Thu, 20-Aug 7:00 AM ET)
Harrow Announces Second Quarter 2026 Financial Results
Globe Newswire (Mon, 10-Aug 4:05 PM ET)
Harrow’s Product Surge Powers Record Demand, but Q1 Revenue Faces One-Time Headwind
Market Chameleon (Tue, 12-May 3:36 AM ET)
Harrow’s TRIESENCE Pushes Forward: Phase 3 Trial Aims to Simplify Post-Cataract Care for Millions
Market Chameleon (Wed, 4-Mar 6:21 AM ET)
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Harrow trades on the NASDAQ stock market under the symbol HROW.
As of November 6, 2026, HROW stock price climbed to $26.89 with 617,938 million shares trading.
HROW has a beta of 2.10, meaning it tends to be more sensitive to market movements. HROW has a correlation of 0.13 to the broad based SPY ETF.
HROW has a market cap of $1.01 billion. This is considered a Small Cap stock.
Last quarter Harrow reported $71 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $160,904 and missed earnings estimates by -$.22.
In the last 3 years, HROW traded as high as $59.23 and as low as $7.60.
The top ETF exchange traded funds that HROW belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWO.
HROW has underperformed the market in the last year with a price return of -21.9% while the SPY ETF gained +10.8%. HROW has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.6% and -5.5%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
HROW support price is $25.02 and resistance is $27.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HROW shares will trade within this expected range on the day.
